Agile up 7% premarket on Twirla refiling

|About: Agile Therapeutics, Inc. (AGRX)|By:, SA News Editor

Agile Therapeutics (NASDAQ:AGRX) has resubmitted its U.S. marketing application for contraceptive patch Twirla.

The company received a CRL in December 2017 citing the need for additional adhesion data.

Shares are up 7% premarket.

Previously: Agile Therapeutics advancing Twirla, to refile U.S. marketing application next quarter (Jan. 10)

Subscribe for full text news in your inbox